Durable and treatment-agnostic muc16 expression in ovarian cancer supports targeted antibody-drug conjugate development

IGCS 2026

Oct 01, 2026
Oncology
Presentation

Kathleen Moore, Lauren Dockery, R. Naumann, David O'Malley, Michelle Rowland, Dayana Delgado, Lennart Langouche, Kathleen Keegan, David Lennon, Ashwini Pai, Dhiren Patel, Robert Coleman

Introduction
Mucin 16 (MUC16), a cell-surface glycoprotein involved in tumor

 

cell proliferation, metastasis, and immune evasion, is overexpressed in ∼80%

 

of epithelial ovarian cancers (OC). Previous analyses showed that MUC16

 

expression is higher than other ADC targets in OC, and remains stable irrespective of platinum-sensitivity status. This study aimed to assess MUC16

 

expression, and that of other ADC targets, before and after standard-of-care

 

treatments in OC.

 

Methods
RNA-sequencing data from a de-identified real-world database

 

(Tempus AI, Inc.) were used to examine MUC16 expression in pre- and posttreatment OC samples (3.0% matched). Median MUC16 expression was

 

quantified as log2(TPM+1).

 

Results
The analysis included 8,267 OC samples. Median MUC16 expression

 

remained high before and after standard-of-care treatments, including platinum/non-platinum chemotherapy, bevacizumab with/without platinum, and

 

PARP inhibitors, with consistently small effect sizes (Figure 1). Other ADC

 

targets (TROP2, FRα, and CLDN6) showed more variable treatment-associated

 

expression than MUC16 across standard-of-care therapies (Figure 2).

 

Conclusion/Implications
MUC16 expression is highly stable over time across

 

standard-of-care therapies for OC, with lower treatment-associated variability

 

than other ADC targets, indicating low susceptibility to therapy-induced

 

modulation. As MUC16 is not downregulated by standard-of-care treatments,

 

MUC16-directed ADCs may be suitable for use both in combination with

 

standard early-line platinum-based treatment and in the relapsed setting.

 

HWK-016, a next-generation ADC targeting the non-shed extracellular domain

 

of MUC16, is currently being evaluated in a phase 1 clinical trial

 

(NCT07470853) in patients with advanced/metastatic solid tumors, including

 

OC. Future analyses aim to identify variables independently associated with

 

MUC16 expression in matched patient samples.